trending Market Intelligence /marketintelligence/en/news-insights/trending/FIvShwAvZVpq0oCLsdHYpw2 content esgSubNav
In This List

Mesoblast heart drug clears interim phase 3 trial

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Mesoblast heart drug clears interim phase 3 trial

Mesoblast Ltd.'s heart failure treatment MPC-150-IM was successful in an interim phase 3 trial.

Given the results, the trial's independent data monitoring committee said it had no safety concerns and that the trial should continue.

The trial is expected to enroll a total of about 600 patients, up from the trial's first 270 patients.